X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gastroenterology & hepatology (192) 192
index medicus (184) 184
humans (180) 180
gastroenterology and hepatology (159) 159
female (106) 106
adult (101) 101
male (101) 101
inflammatory bowel disease (98) 98
crohn's disease (90) 90
ulcerative colitis (87) 87
inflammatory-bowel-disease (76) 76
middle aged (76) 76
infliximab (69) 69
crohn disease - drug therapy (56) 56
crohns-disease (51) 51
treatment outcome (49) 49
ulcerative-colitis (47) 47
adalimumab (46) 46
abridged index medicus (43) 43
adolescent (41) 41
aged (41) 41
young adult (40) 40
therapy (36) 36
care and treatment (35) 35
maintenance therapy (35) 35
risk factors (32) 32
severity of illness index (32) 32
antibodies, monoclonal - therapeutic use (31) 31
remission induction (29) 29
colitis, ulcerative - drug therapy (28) 28
remission (27) 27
diseases of the digestive system. gastroenterology (26) 26
clinical trials (25) 25
crohns disease (25) 25
inflammatory bowel diseases (25) 25
risk (25) 25
crohn’s disease (24) 24
gastrointestinal agents - therapeutic use (24) 24
anti-inflammatory agents - therapeutic use (23) 23
double-blind (23) 23
time factors (23) 23
analysis (22) 22
gastroenterology (22) 22
management (22) 22
prevalence (22) 22
gastrointestinal diseases (21) 21
surgery (21) 21
certolizumab pegol (20) 20
double-blind method (20) 20
original (20) 20
prognosis (20) 20
medical research (19) 19
retrospective studies (19) 19
antibodies, monoclonal, humanized (18) 18
endoscopy (18) 18
epidemiology (18) 18
ibd (18) 18
immunosuppressive agents - therapeutic use (18) 18
maintenance (18) 18
tumor necrosis factor-alpha - antagonists & inhibitors (18) 18
azathioprine (17) 17
colonoscopy (17) 17
efficacy (17) 17
follow-up studies (17) 17
metaanalysis (17) 17
patients (17) 17
placebo-controlled trial (17) 17
antibodies, monoclonal - adverse effects (16) 16
case-control studies (16) 16
crohn disease (16) 16
quality of life (16) 16
safety (16) 16
studies (16) 16
antibodies, monoclonal - administration & dosage (15) 15
incidence (15) 15
inflammatory bowel diseases - drug therapy (15) 15
quality-of-life (15) 15
antibodies, monoclonal, humanized - therapeutic use (14) 14
association (14) 14
c-reactive protein (14) 14
crohn disease - diagnosis (14) 14
crohn disease - therapy (14) 14
induction (14) 14
medicine, experimental (14) 14
medicine, general & internal (14) 14
pharmacology & pharmacy (14) 14
aged, 80 and over (13) 13
biopsy (13) 13
canada (13) 13
colitis, ulcerative - surgery (13) 13
crohn disease - epidemiology (13) 13
crohn disease - pathology (13) 13
crohn disease - surgery (13) 13
inflammation (13) 13
rheumatoid-arthritis (13) 13
treatment (13) 13
anti-tnf (12) 12
colitis (12) 12
diagnosis (12) 12
digestive system diseases (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Journal Article
Gut, ISSN 0017-5749, 05/2017, Volume 66, Issue 5, pp. 839 - 851
ObjectiveVedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an... 
INFLAMMATORY-BOWEL-DISEASE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | OPPORTUNISTIC INFECTIONS | FOLLOW-UP | RISK | EXPERIENCE | COHORT | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | ADVERSE EVENTS | MAINTENANCE THERAPY | Tuberculosis - epidemiology | Age Factors | Humans | Middle Aged | Male | Narcotics - therapeutic use | Clostridium Infections - epidemiology | Adrenal Cortex Hormones - therapeutic use | Incidence | Young Adult | Treatment Failure | Infusions, Intravenous - adverse effects | Gastrointestinal Agents - immunology | Adult | Female | Colitis, Ulcerative - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Factors | Sepsis - epidemiology | Chemical and Drug Induced Liver Injury - epidemiology | Randomized Controlled Trials as Topic | Crohn Disease - drug therapy | Gastrointestinal Agents - therapeutic use | Gastrointestinal Agents - adverse effects | Antibodies, Monoclonal, Humanized - immunology | Antibodies, Neutralizing - blood | Leukoencephalopathy, Progressive Multifocal - epidemiology | Neoplasms - epidemiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug therapy | Crohn's disease | Ulcerative colitis | Clinical trials | Infections | Malignancy | Patients | Risk factors | Crohns disease | Inflammatory bowel disease | Studies | Tuberculosis | Tumor necrosis factor | Population | Tumor necrosis factor-TNF | TNF inhibitors | Sepsis | Safety | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus | 1506 | Inflammatory Bowel Disease
Journal Article
Gut, ISSN 0017-5749, 06/2011, Volume 60, Issue 6, pp. 780 - 787
Journal Article
Gut, ISSN 0017-5749, 10/2009, Volume 58, Issue 10, p. S21
Journal Article
The Lancet, ISSN 0140-6736, 12/2017, Volume 390, Issue 10114, pp. 2779 - 2789
Journal Article
Gastroenterology & hepatology, ISSN 1554-7914, 08/2013, Volume 9, Issue 8, pp. 529 - 532
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 16, pp. 1519 - 1528
Journal Article
Gut, ISSN 0017-5749, 06/2017, Volume 66, Issue 6, pp. 1049 - 1059
Journal Article